Drugs / ADCX-020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07238075 | Feb 2026 → Jul 2029 expected | cancer, metastatic neoplasm | Adcytherix SAS | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | Adcytherix SAS | Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth adcytherix.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADCX-020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07238075 ↗ |
| Modality | Other / unclassified | “antibody drug conjugate” NCT07238075 ↗ |
| Route | Intravenous | “intravenous” NCT07238075 ↗ |